How should elevated iron levels be evaluated and managed?

Evaluation and Management of Elevated Iron Levels

Begin evaluation of elevated iron levels by measuring both transferrin saturation and serum ferritin, then proceed with HFE genetic testing (C282Y and H63D mutations) to identify hereditary hemochromatosis, which requires therapeutic phlebotomy to prevent life-threatening complications including cirrhosis, hepatocellular carcinoma, and cardiac disease. 1

Initial Diagnostic Approach

Biochemical Assessment

• Measure transferrin saturation and serum ferritin simultaneously - elevated transferrin saturation is characteristic of hemochromatosis and indicates disturbed plasma iron homeostasis, while ferritin elevation can reflect either iron overload or non-specific causes including inflammation and malignancy 2

• Recognize that serum iron parameters alone are insufficient - ferritin is elevated in inflammatory and neoplastic conditions independent of iron stores, requiring tissue iron assessment for definitive diagnosis 2

Genetic Testing

• Order HFE gene mutation analysis for C282Y and H63D variants in all patients with elevated transferrin saturation and ferritin 3

• Understand the genetic patterns: C282Y homozygotes represent the classic hereditary hemochromatosis phenotype, while compound heterozygotes (C282Y/H63D) account for 14-30% of patients referred for phlebotomy 2

• Note that H63D homozygosity rarely causes significant iron overload - only 3.2% develop true iron overload, and high ferritin is uncommon in these patients 2

Advanced Imaging and Tissue Assessment

MRI for Iron Quantification

• Use MRI with R2 sequences to quantify hepatic iron concentration* in patients with unclear etiology of hyperferritinemia, biochemical iron overload, or positive liver iron staining 2

• MRI provides critical information beyond diagnosis - hepatic iron concentration predicts total body iron stores and the number of phlebotomies required for treatment 2

• Perform cardiac MRI in patients with signs of heart disease or juvenile hemochromatosis - cardiac disease is a leading cause of death, and liver iron does not correlate with cardiac iron stores 2, 4

• Assess extrahepatic organ involvement including spleen, pancreas, and brain when indicated 2

Liver Biopsy Indications

• Perform liver biopsy in C282Y homozygotes or compound heterozygotes if:

  • Serum ferritin >1,000 μg/L 2, 1
  • ALT or AST are elevated 1

• Liver biopsy is essential for non-HFE iron overload to determine the degree and cellular distribution of iron, which guides diagnosis and prognosis 1

• Do not perform liver biopsy if cirrhosis is already clinically evident - it adds no diagnostic value 2

Treatment Strategy

Therapeutic Phlebotomy for Hereditary Hemochromatosis

Initiate weekly phlebotomy (one unit of 450-500 mL blood) as tolerated in all patients with confirmed hemochromatosis and iron overload - this prevents cirrhosis, hepatocellular carcinoma, diabetes, and cardiac disease, which are the primary causes of mortality 1

Phlebotomy Protocol

• Remove one unit weekly until serum ferritin reaches 50-100 μg/L 1

• Monitor hemoglobin or hematocrit before each phlebotomy - do not allow reduction to <80% of baseline value 1

• Check serum ferritin every 10-12 phlebotomies (approximately every 3 months) during initial treatment 1

• Increase monitoring frequency as ferritin approaches target range to prevent iron deficiency 1

Maintenance Therapy

• Continue maintenance phlebotomy to keep ferritin between 50-100 μg/L - frequency varies from monthly to 1-2 units per year depending on individual iron reaccumulation rates 1

• Not all patients reaccumulate iron - assess individually for maintenance needs 1

Special Populations

• C282Y homozygotes with ferritin <1,000 μg/L and normal liver enzymes can proceed directly to phlebotomy without liver biopsy 1

• Patients with end-organ damage require the same phlebotomy endpoints despite existing complications 1

Treatment of Secondary Iron Overload

When Phlebotomy is Beneficial

• Porphyria cutanea tarda (PCT): Phlebotomy is clearly indicated and reduces skin manifestations 1

• Non-alcoholic fatty liver disease (NAFLD): Phlebotomy improves insulin resistance parameters and reduces elevated ALT levels 1

• Chronic hepatitis C: Phlebotomy reduces ALT and marginally improves histopathology but does not affect viral clearance 1

When Phlebotomy is NOT Recommended

• Alcoholic liver disease (ALD): No published evidence supports benefit 1

• Mild secondary iron overload in hepatitis C (hepatic iron concentration <2,500 μg/g dry weight): Phlebotomy is not recommended 1

Iron Chelation Therapy

• Use deferoxamine (20-40 mg/kg/day subcutaneously) for secondary iron overload due to ineffective erythropoiesis including β-thalassemia 1

• Deferasirox (oral) is approved for transfusional iron overload but concerns about complications limit enthusiasm for use in hereditary hemochromatosis 1

Critical Management Points

Dietary Modifications

• Avoid vitamin C supplements - enhances iron absorption 1

• Avoid iron supplements and excess vitamin C 1

• Avoid raw shellfish - risk of Vibrio vulnificus infection in iron-overloaded patients 1

• Dietary adjustments beyond these restrictions are unnecessary 1

Monitoring for Complications

• Screen patients with cirrhosis for hepatocellular carcinoma even after successful iron depletion - HCC accounts for 30% of hemochromatosis-related deaths and risk persists despite treatment 1

• HCC is exceptionally rare in non-cirrhotic hemochromatosis - this underscores the importance of early treatment before cirrhosis develops 1

Expected Treatment Responses

Symptoms that improve with phlebotomy: 1

• Malaise and fatigue
• Skin pigmentation
• Insulin requirements in diabetics
• Abdominal pain
• Cardiac function

Symptoms with limited or no response: 1

• Arthropathy (minimal improvement)
• Hypogonadism (minimal improvement)
• Advanced cirrhosis (no reversal)
• Testicular atrophy (no reversal)

Hepatic fibrosis may reverse in approximately 30% of cases with adequate iron removal 1

Common Pitfalls

• Do not rely on ferritin alone - it is elevated in inflammation, malignancy, and chronic liver disease independent of iron stores 2

• Do not assume all hyperferritinemia represents iron overload - evaluate for secondary causes including metabolic syndrome, alcohol excess, and inflammatory conditions 2

• Recognize that patients with metabolic syndrome or alcohol excess may have iron overload, but evidence does not support phlebotomy in these populations 2

• Consider liver transplantation for decompensated cirrhosis - adequate iron removal before transplantation improves perioperative survival 1